Chris is a world-renowned drug hunter with over 30 years of experience in drug design and development. After receiving his Ph.D. degree from Princeton University, he served as Director of Medicinal Chemistry in small biotech (Sugen) and big pharma (Pharmacia/Pfizer), and Scripps Florida. As the chief scientific officer, he founded Xcovery in Palm Beach, Florida, in 2006, and pioneered the virtual drug discovery model. His major accomplishments include: the principal inventor of sunitinib which was approved worldwide in 2006 and had annual sales of >$1 billion; inventor of ensartinib which was approved in China and the USA; inventor of vorolanib which was approved in China; inventor of the first highly potent and selective, brain penetrant dual TYK2/JAK1 inhibitor, and other compounds in Highlightll pipeline.

Dr. Junmin "Jay" Huang is the Vice President of CMC-Quality.  He has more than 15 years of experience in drug discovery and development with expertise in chemistry, manufacturing, CMC/quality controls and regulatory affairs.  Before joining Highlightll, he worked as a post-doctoral fellow at Vanderbilt University and Mississippi State University, followed by drug research and development in pharmaceutical industries at Synta, Sanofi, Boehringer Ingelheim, Xcovery, and Zenshine Pharmaceuticals with increasing responsibilities from scientist to VP. Over the years, he has successfully filed 2 NDAs, managed 10 products in US FDA and EU EMA post-approvals, and more than 30 IND projects. Dr. Huang received his Ph.D. in organic chemistry from Nankai University and an MBA in Pharmaceutical Management from Rutgers Business School.

Dr. Tang has nearly 20 years of experience in drug discovery and development, expertise in biology, pharmacology, and biomarker studies. She has been a key member in the pre-clinical and clinical development of some programs in oncology or autoimmune diseases. Before joining Highlightll, she was the VP of research at ACEA Pharmaceutical. Before that, she was a research scientist at U.T. Southwestern Medical Center. Dr. Tang received her Ph.D. in Molecular Biology and Biochemistry from the Institute of Biophysics, Chinese Academy of Sciences. 

Mr. Yong Liu leads the planning, execution and management of our clinical trials and patient care coordination. Mr. Liu brings more than two decades of leadership in clinical trial execution across China's biotech sector. He previously served as senior director at Betta Pharmaceuticals (300558.SZ) and clinical director at Sino Biopharmaceutical Limited (1177.HK), where he led the strategy and successful registration of icotinib and ensartinib. His insights into clinical governance and operational delivery support our ongoing trials and regulatory execution. Mr. Liu graduated with a degree in Clinical Medicine from Wuhan University in China.

Ms. Sunny Ren leads the commercialization of our products in Mainland China, including strategy, planning, management and execution. She has over a decade of experience in marketing, sales, deep customer insights and industry expertise within the dermatology, autoimmune and respiratory therapeutic areas. Ms. Ren was instrumental in the successful launch of dupilumab (Dupixent) in China during her tenure at Sanofi. At Abbvie, she was responsible for the marketing of upadacitinib (RINVOQ) in dermatology, establishing its brand leadership through differentiated competitive strategies. Ms. Ren also led the commercialization of Stapokibart (CM310), China's first IL-4Rα inhibitor, while she was with Keymed Biosciences. Ms. Ren graduated from Tianjin University of Traditional Chinese Medicine and subsequently earned her MBA from The Open University in the UK.

Mr. Liujun Song is responsible for overseeing the licensing, collaboration and global market expansion of company's pipeline projects. Mr. Song previously held business development roles at Hansoh Pharma, HBM Holdings Limited (02142.HK), and METiS Pharmaceuticals. At HBM Holdings Limited, he led the completion of more than ten licensing deals for technology platforms and products. Notably, he led the out-licensing of the Greater China rights for the Phase III clinical asset HBM9161(FcRn) to CSPC Pharmaceutical Group. Mr. Song holds a Master's degree from China Pharmaceutical University and subsequently earned his MBA from China Europe International Business School.